Bendazac
| Code | Size | Price |
|---|
| TAR-T7807-100mg | 100mg | £103.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Bendazac is an anticataract drug. It may act by preventing protein denaturation.
CAS:
20187-55-7
Formula:
C16H14N2O3
Molecular Weight:
282.299
Purity:
0.9813
SMILES:
OC(=O)COc1nn(Cc2ccccc2)c2ccccc12
References
Lewis B S , Rixon K C , Harding J J . Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract[J]. Experimental Eye Research, 1986, 43(6):0-979.
Marques C , Ramalho J S , Pereira P , et al. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac[J]. Documenta Ophthalmologica, 1995, 90(4):395-404.